Introduction
============

Along with limitations in respiratory capacity, peripheral or limb-muscle dysfunction is a widely recognized consequence of COPD,[@b1-copd-13-2685] causing particularly quadriceps-muscle weakness.[@b2-copd-13-2685],[@b3-copd-13-2685] A reduction of 30% in quadriceps muscular force among the patients with COPD has been observed when compared to healthy elderly volunteers.[@b4-copd-13-2685] This is mainly attributed to reduction in lean mass and a decrease in the cross-sectional area of the muscle,[@b5-copd-13-2685],[@b6-copd-13-2685] as well as decreased muscular endurance and increased susceptibility to fatigue,[@b7-copd-13-2685] further worsening a sedentary lifestyle. It has also been observed that despite the respiratory problems, individuals with COPD stop exercise, not due to the breathlessness, but rather due to the perception of leg fatigue.[@b8-copd-13-2685] The prevalence of reduced quadriceps strength has also been reported in other chronic diseases such as diabetes[@b9-copd-13-2685] and chronic heart failure (CHF),[@b10-copd-13-2685] serving as a predictor of mortality in the latter[@b11-copd-13-2685] and in COPD.[@b12-copd-13-2685] Moreover, quadriceps muscular force represents a valuable target to measure, as it allows identification of responders to a pulmonary rehabilitation program (PRP).[@b13-copd-13-2685] Among the different techniques[@b14-copd-13-2685] to measure quadriceps strength, the use of a handheld dynamometer[@b15-copd-13-2685] for the evaluation of quadriceps maximal voluntary contraction (QMVC), where resistance is applied by the operator either directly on the device[@b16-copd-13-2685] or by the use of straps,[@b17-copd-13-2685] is known to be a simple and reproducible method.[@b18-copd-13-2685] The technique, though well known as a handheld method, also accepts the use of a stabilization belt to fix the dynamometer on a rigid support that limits operator-induced bias.[@b19-copd-13-2685] The simplicity of this method makes it possible to conduct this measurement in any clinical setting with minimal equipment. Despite its usage over rather a long time, we lack information on what an improvement in this measure really signifies for patients.

There have been previous studies on the evolution of quadriceps strength after a rehabilitation program in chronic diseases, such as diabetes[@b20-copd-13-2685] and CHF.[@b21-copd-13-2685] In COPD, a significant increase in quadriceps strength by 8% following aerobic training and 20% following combined aerobic and strength training have been identified.[@b22-copd-13-2685] Although differing in methodology of measurement, the study of change in quadriceps strength after an intervention of rehabilitation is of great value. However, its minimally important difference (MID) remains unknown. The MID is a useful expression defined as "the minimal amount of change required between two points in time to be confident that a patient has truly changed".[@b23-copd-13-2685] A reduction of 4% in isometric force has been suggested as the minimal change to bring about a relevant difference in osteoarthritis of the knee.[@b24-copd-13-2685] Similarly, a preliminary result by Quessada et al suggested an MID of 33 Nm for QMVC in individuals with COPD undergoing exercise training.[@b25-copd-13-2685] As preliminary data from a small sample, these results and the insight on the technique of measurement remain to be confirmed in a larger population. From this perspective, we aimed to determine the MID for QMVC using a simple fixed dynamometer in individuals with COPD undergoing a PRP.

Methods
=======

Subjects
--------

Patients were included in the study if they fulfilled the inclusion criteria of a diagnosis of COPD according to the Global initiative for Chronic Obstructive Lung Disease (GOLD) recommendations,[@b26-copd-13-2685] having completed a PRP including exercise training and education component as recommended,[@b27-copd-13-2685] and written consent signed by the patient prior to the beginning of the program. Patients from Nantes were included in the cohort RehaEffort from the Institut de Recherche en Santé Respiratoire des Pays de la Loire and patients from North Brittany were from the Centre Hospitalier des Pays de Morlaix. Exclusion criteria were the presence of a lower-limb lesion hampering the measurement of quadriceps strength and the presence of joint limitations. The patients were recruited in three different centers in two cities of France: the University Hopsital of Nantes and the Tourmaline Medical Centre in Nantes and the Centre Hospitalier des Pays de Morlaix in Morlaix. In Nantes, the study was conducted by the RehaEffort cohort group from the Institut de Recherche en Santé Respiratoire des Pays de la Loire, for which approval was obtained from the ethical board (Comité de Protection des Personnes \[CPP\] -- 2009/17) and the Comité Consultatif sur le Traitement de l'Information en Matière de Recherche dans le Domaine de la Santé \[CCTIRS\] (07.207 bus). Patients from the Centre Hospitalier des Pays de Morlaix signed a written informed consent in accordance with the Declaration of Helsinki and the current guidelines for Good Clinical Practice after approval by the institutional medical ethics committees (CPP Ouest 6 -- CPP803, 2013-A01180-45).

Study design
------------

All patients included went through a complete outpatient or inpatient evaluation in the institutions to assess individual deficiency, incapacity, and social disadvantage, as recommended.[@b27-copd-13-2685] Pulmonary function tests, including spirometry, plethysmography, and diffusion capacity, were conducted according to European Respiratory Society and American Thoracic Society task-force recommendations.[@b28-copd-13-2685],[@b29-copd-13-2685] All patients performed a cardiopulmonary exercise test using a progressive 10 W incremental test on an electromagnetically braked cycle ergometer up to exhaustion, as recommended.[@b30-copd-13-2685] A 6-minute walk test (6MWT) was also performed, and dyspnea was assessed using the Modified Medical Research Council (mMRC) scale. Evaluation of health-related quality of life (HRQoL) was done with St George's respiratory questionnaire (SGRQ) total score, and anxiety and depression with Hospital Anxiety and Depression Scale (HADS) total score. Along with these, nutritional assessment, evaluation of comorbidities, and treatments were done. Evaluation of exercise capacity, dyspnea, HRQoL, anxiety, and depression were conducted at baseline and the end of the PRP.

Pulmonary rehabilitation
------------------------

All the centers included in the study followed the standard-ized PRP as per the recommendations,[@b31-copd-13-2685] with variations in their modalities, including home-based, center-based, and outpatient-based programs in Nantes and center-based or outpatient-based programs in Morlaix. A further description of the PRP content is provided in the Supplementary material.

Quadriceps maximal voluntary contraction
----------------------------------------

For measurement of QMVC, an adaptation of the well-established method using a MicroFET2 dynamometer (Hoggan Scientific, Salt Lake City, UT, USA) was used.[@b19-copd-13-2685] To ensure proper measurement, the patient sat comfortably on the examination table with a high-density triangular corner cushion under the knees, in order to guarantee alignment of the femur and provide countersupport at the knees. Hip and knee were positioned at 90° flexion.[@b32-copd-13-2685] The device was fixed on the leg of the examination table with a strap to prevent any operator bias. A second strap was then used to fix the leg to the device. The point of application of force was 5 cm above the medial malleolus of the tibia. The moment of force was calculated with measurement of the lever arm between the knee-joint center and the point of application of force. As the measure of QMVC is known to have a learning effect,[@b33-copd-13-2685] a minimum of three measures was obtained for each leg. The best value obtained was then taken as the absolute value. These measurements are expressed in Newton meters.

Statistical analysis
--------------------

All results are presented as means ± SD or percentages. Comparison of baseline characteristics among the three centers was done by one-way analysis of variance (ANOVA). Variables that changed significantly from baseline to the end of the PRP were identified by paired *t*-tests in cases of normality of distribution of values or the Wilcoxon test if not normally distributed. All statistical analyses were performed using SigmaPlot 11.0 and SPSS Statistics 19 (IBM, Armonk, NY, USA). QMVC and the 6-minute walk distance (6MWD) measurements were standardized using *z*-scores. A *z*-score gives a quantified distance from the normative data in the SD in respect to the average reference performance of the population selected, which means that *z*-scores help us to compare the observed value of measurement to a normal population. A *z*-score of −1.64 signifies that the value measured lies in the fifth percentile.

The equation used was *z*-score = (Observed value -- Predicted value)/SD. The predicted value for QMVC was taken from Hogrel et al[@b34-copd-13-2685] and for 6MWD from Troosters et al.[@b35-copd-13-2685] Statistical significance of comparisons was set at *P*\<0.05.

Calculation of MID
------------------

For MID estimation, distribution- and anchor-based methods were used.[@b36-copd-13-2685] The distribution-based method uses the distribution of observed values in a given sample to estimate MID. Distribution-based methods used in this study were empirical rule effect size (0.08×6×SD~end--baseline~) and Cohen's effect size (0.5×SD~end--baseline~). The anchor-based method uses an external indicator with its known MID in the target population. In this study, the possible anchors were 6MWD, with its MID of 30 m,[@b37-copd-13-2685] and SGRQ total score, with its MID of −4 points.[@b38-copd-13-2685] For a potential anchor to be selected using this approach as per recommendations, the change from baseline must correlate with the change in QMVC with a correlation coefficient ≥0.3 and *P*\<0.05.[@b36-copd-13-2685]

Results
=======

A total of 157 eligible individuals with COPD were included in the study from February 2014 to January 2016. The characteristics of the subjects included are given in [Table 1](#t1-copd-13-2685){ref-type="table"}. Comparison of baseline characteristics among the three centers is given in [Table S1](#SD1-copd-13-2685){ref-type="supplementary-material"}.

Responsiveness to PRP
---------------------

Changes in parameters between baseline and the end of the PRP are given in [Table 2](#t2-copd-13-2685){ref-type="table"}. Subjects improved quadriceps force, 6MWD, and HRQoL significantly. Comparison of the intervention effect on the parameters evaluated at baseline and the end of the PRP at the three centers is given in [Table S2](#SD2-copd-13-2685){ref-type="supplementary-material"}.

Evolution of QMVC and 6MWD *z*-scores
-------------------------------------

There was significant evolution in QMVC and 6MWD *z*-scores between baseline and the end of the PRP (−0.8±0.7 to −0.4±0.7 \[*P*\<0.001\] for QMVC and −1.7±1.1 to −1.4±1.0 \[*P*\<0.001\] for 6MWD; [Figure 1](#f1-copd-13-2685){ref-type="fig"}). At the end of the PRP, subjects had improved their 6MWD, and average *z*-score (−1.4±1.0) was found to be within the 90th percentile.

Determination of MID
--------------------

Using distribution-based methods, the MID for QMVC was 7.5 Nm for empirical rule effect size and 7.8 Nm for Cohen's effect size. The change in QMVC failed to correlate with either the change in 6MWD (*r*=−0.032, *P*=0.686) or with change in SGRQ total score (*r*=0.006, *P*=0.937). As such, no anchor could be identified in this analysis. The distribution of the subjects with the changes in 6MWD and SGRQ total scores in terms of the MID of 7.5 Nm in QMVC and MIDs of 30 m for 6MWD and −4 points for the SGRQ is given in [Figure 2](#f2-copd-13-2685){ref-type="fig"}.

Discussion
==========

In this study, we report the MID for QMVC in individuals with COPD undergoing a PRP. Our findings suggest 7.5 Nm to be the minimal change in QMVC attributed to the intervention of a PRP. Even though the measure of QMVC has been in place for a long time, a question remains as to what this measure actually means with regard to meaningful improvement for a patient and how the person perceives this muscular force in daily life. The diminution in muscular force with disease progression is common among individuals with COPD. Therefore, the assessment of quadriceps force seems relevant, especially if the interest is to evaluate the effect of such an intervention as a rehabilitation program. The measure of quadriceps force appears of interest along with the evaluation of daily activity in chronic diseases, as movement like getting up from a chair and moving around involves the use of quadriceps muscles. We previously found a significant correlation between changes in QMVC after a PRP and 1-minute sit-to-stand test,[@b39-copd-13-2685] which involves repeated contractions of quadriceps muscles for a longer time, requiring force and endurance capacities. Apart from activities of daily living, good quadriceps muscular force can also reduce the risk of falls in these patients. Studies have shown strong correlations between lower-limb-muscle weakness and increased fall incidence among elderly people.[@b40-copd-13-2685] In COPD, an increased risk of falls is associated with quadriceps weakness resulting from exacerbation and related hospitalization.[@b41-copd-13-2685] This further adds to the interest of QMVC measurement in COPD. The evaluation of QMVC by dynamometer in our study was performed by fixing the device with a strap to the leg of the examination table to avoid operator-influenced bias. It is important to note that the handheld method using this device is known to be influenced by the strength of the operator when applied manually.[@b42-copd-13-2685]

Our study estimated the MID of QMVC in individuals with COPD. To our knowledge, this is the first study to address MID calculation for QMVC in COPD. There have been a few studies that focused on the evolution of quadriceps strength after an intervention. Nishitani et al provided evidence of an improvement in muscle strength in individuals with diabetes mellitus after cardiac rehabilitation of 6 months following coronary artery-bypass grafting.[@b20-copd-13-2685] Similarly, in individuals with CHF and COPD, evolution of quadriceps strength was compared between an exercise rehabilitation of 7 weeks and usual care. There was no difference between groups, perhaps because the exercise program included mainly endurance training, as justified by the authors.[@b21-copd-13-2685] Ber-nard et al showed a significant increase of 20% in quadriceps strength following aerobic and strength training in COPD.[@b22-copd-13-2685] Despite studies including quadriceps-strength measurement in COPD and pulmonary rehabilitation, a possible MID has been less explored. All these studies also differed in the method of evaluation of quadriceps strength. We found a preliminary report on MID for QMVC in COPD by Ques-sada et al, where the technique of measurement was not provided in detail and thus cannot be presumed to be totally comparable.[@b25-copd-13-2685]

The estimation of MID in our study was done using distribution-based methods only, as the change in QMVC and the possible anchors failed to correlate. In this study, we chose the 6MWD and SGRQ as possible anchors, due to their known MID and relevance in the COPD population undergoing a PRP. QMVC expresses maximal strength of the muscle, whereas the 6MWD is an aerobic functional test. The reorganization of muscle-fiber type in COPD, as per Gosker et al,[@b43-copd-13-2685] could also result in differences in performance during these two evaluations, suggesting that they evaluate different dimensions of functional capacity. Quadriceps force has been identified as a determinant of 6MWD,[@b44-copd-13-2685] but it should be noted that our interest lies in the comparison between the change measured in each of these evaluations. The low correlation between changes in QMVC and 6MWD suggests that evolution of either of the evaluations is not correlated with the other, further confirming a difference in the dimensions that they measure. Similarly, variability in the correlation between a physical performance and QoL has previously been shown,[@b45-copd-13-2685] which could agree with our nonsignificant correlation between QMVC and SGRQ. It is however usual for MID calculation to be based on the distribution of observed scores. Similar methods have been used to calculate MIDs for exercise tests in COPD, such as the 6MWT and 6-minute stepper test.[@b46-copd-13-2685],[@b47-copd-13-2685] These statistical methods, based on distribution of values, resulted in variation in MID from 7.5 Nm to 7.8 Nm. Taking these MID ranges into account, \>50% of subjects were able to improve their quadriceps force after the PRP. It should also be noted that our study focused on the minimally significant change for an improvement in QMVC and not deterioration. The interpretation of improvement and deterioration may not be likely to be similar when presented in a patient-reported outcome, which is often used in the anchor-based MID estimation. This variation could result in different MIDs for improvement and deterioration of a measure.[@b48-copd-13-2685] The MID estimation, however, in our study gives a cutoff value for improvement of quadriceps strength.

It appears important to distinguish the different MID calculations and to analyze their advantages and limits. Copay et al[@b49-copd-13-2685] listed three limitations of MID determinations: each method estimates a different MID value, MID calculation does not consider the cost of the treatment (further studies are necessary to investigate this point), and the change in patient-reported outcome depends on the baseline status of the patient. Along with these, the study had some limitations. The first is the absence of a control group. The findings of this study could have been strengthened with a control group. The second limitation is the difference in duration of the PRP among the centers. A center effect is not excluded, but probably limited here by the fact that the subjects recruited in all three centers had similar baseline characteristics, which made it possible to combine the observed values. This approach justifies the interest of a multicenter study. Although there were some differences in duration, the program content was as per the recommendations in all the centers, thus leading to similar changes observed after the PRP whatever the origin of the patients. Moreover, our results showed that all PRPs produced significant improvements, which is comparable to previous studies.[@b50-copd-13-2685],[@b51-copd-13-2685] The third limitation is the absence of follow-up data after the PRP. Further studies are required to investigate the long-term maintenance of muscle-strength improvement.

Conclusion
==========

Assessment of QMVC using a fixed dynamometer is a simple evaluation of quadriceps muscular force and capable of assessing improvement after a PRP among COPD patients. A gain of at least 7.5 Nm represents a meaningful improvement in quadriceps force after a PRP.

Supplementary materials
=======================

Pulmonary rehabilitation
------------------------

The home-based pulmonary rehabilitation program (PRP) was conducted for 12 weeks, 2 days per week, center-based PRP for 4 weeks, 3 days per week, outpatient-based PRP for 6 weeks, 3 days per week in the centers in Nantes, and center-based or outpatient PRP in Morlaix for 4 weeks, 5 days per week. The standardized PRP in all the centers included aerobic exercise on a cycle ergometer and/or treadmill with a target intensity of 60% peak work rate regarded as minimum and resistance training of the upper-and lower-limb muscles for 30--45 minutes.[@b52-copd-13-2685],[@b53-copd-13-2685] Along with these, respiratory physiotherapy, a therapeutic educational program, dietary counseling, a smoking-cessation program and sociopsychological support were also included in the PRP.

###### 

Baseline characteristics of the patients from three centers

                         Nantes    Morlaix                                               
  ---------------------- --------- ----------------------------------------------------- ------------------------------------------------------
  n                      18        20                                                    119
  Male/female            15/3      12/8                                                  66/53
  Age, years             63±7      63±10                                                 63±9
  BMI, kg/m^2^           25±6      25±6                                                  26±6
  Dyspnea, mMRC          3±1       2±1                                                   2±1[\*](#tfn5-copd-13-2685){ref-type="table-fn"}
  Lung function                                                                          
   FEV~1~, % predicted   48±22     48±17                                                 47±18
   FVC, % predicted      77±21     75±22                                                 78±24
   FEV~1~/FVC, %         48±14     29±28                                                 48±12
   GOLD 1, n (%)         1 (6)     1 (5)                                                 6 (5)
   GOLD 2, n (%)         5 (28)    8 (40)                                                45 (38)
   GOLD 3, n (%)         10 (56)   9 (45)                                                45 (38)
   GOLD 4, n (%)         2 (11)    2 (10)                                                27 (17)
   QMVC, Nm              92±25     99±30                                                 96±40
   6MWD, m               304±101   443±108[‡](#tfn6-copd-13-2685){ref-type="table-fn"}   397±101[\*](#tfn5-copd-13-2685){ref-type="table-fn"}
   6MWD, % predicted     53±17     76±20[‡](#tfn6-copd-13-2685){ref-type="table-fn"}     69±18[\*](#tfn5-copd-13-2685){ref-type="table-fn"}
   SGRQ total score      64±15     52±18                                                 52±16[\*](#tfn5-copd-13-2685){ref-type="table-fn"}
  HADS                                                                                   
   Anxiety               9±4       8±4                                                   8±5
   Depression            7±4       6±4                                                   7±4
   Total                 16±7      14±6                                                  15±7
  BODE index             5±2       4±2                                                   3±2

**Notes:**

*P*\<0.05, significant difference between University Hospital of Nantes' and Morlaix;

*P*\<0.05, significant difference between University Hospital of Nantes and Tourmaline Medical Centre. Data presented as mean ± SD unless otherwise indicated. Predicted values for 6MWD taken from Troosters et al.[@b54-copd-13-2685]

**Abbreviations:** BODE, body mass, airflow obstruction, dyspnea, and exercise; BMI, body-mass index; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HADS, Hospital Anxiety and Depression Scale; mMRC, modified Medical Research Council (scale); QMVC, quadriceps maximal voluntary contraction; 6MWD, 6-minute walk distance; SGRQ, St George's respiratory questionnaire.

###### 

Comparison of the changes in parameters measured at baseline and the end of PRP in the three centers

                Nantes    Morlaix                                                                                                                                                                              
  ------------- --------- --------- ------- ----------------------------------------------------- --------- -------- -------- ---------------------------------------------------- --------- --------- ------- ------------------------------------------------------------------------------------------------
  QMVC, Nm      92±25     108±26    16±10   19±14[\*](#tfn8-copd-13-2685){ref-type="table-fn"}    99±30     116±40   17±16    17±15[\*](#tfn8-copd-13-2685){ref-type="table-fn"}   96±40     103±42    7±16    8±20[\*](#tfn8-copd-13-2685){ref-type="table-fn"},[‡](#tfn9-copd-13-2685){ref-type="table-fn"}
  6MWD, m       304±101   361±89    36±88   13±27                                                 443±108   480±96   36±48    11±19[\*](#tfn8-copd-13-2685){ref-type="table-fn"}   397±101   441±100   43±43   13±14[\*](#tfn8-copd-13-2685){ref-type="table-fn"}
  SGRQ total    64±15     52±20     −7±8    −12±14[\*](#tfn8-copd-13-2685){ref-type="table-fn"}   52±18     44±13    −11±21   −16±45                                               52±16     44±15     −8±12   −13±25[\*](#tfn8-copd-13-2685){ref-type="table-fn"}
  HADS                                                                                                                                                                                                         
   Anxiety      9±4       6±4       −2±3    −29±33[\*](#tfn8-copd-13-2685){ref-type="table-fn"}   8±4       7±3      −2±4     −2±61                                                8±5       7±4       −2±3    −15±47[\*](#tfn8-copd-13-2685){ref-type="table-fn"}
   Depression   7±4       6±4       0±2     18±64                                                 6±4       7±4      0±2      2±34                                                 7±4       5±4       −2±3    −19±51[\*](#tfn8-copd-13-2685){ref-type="table-fn"}
   Total        16±7      12±7      −2±3    −18±22[\*](#tfn8-copd-13-2685){ref-type="table-fn"}   14±6      14±6     −2±6     −10±44                                               15±7      12±7      −3±6    −19±39[\*](#tfn8-copd-13-2685){ref-type="table-fn"}

**Notes:**

*P*\<0.05 between baseline and end of PRP;

*P*\<0.05, significant difference between Nantes and Morlaix. Data presented as mean ± SD.

**Abbreviations:** HADS, Hospital Anxiety and Depression Scale; 6MWD, 6-minute walk distance; PRP, pulmonary rehabilitation program; QMVC, quadriceps maximal voluntary contraction; SGRQ, St George's respiratory questionnaire.

The authors would like to acknowledge colleagues from the following teams who were involved in taking care of the patients in pulmonary rehabilitation and assisting with inclusion: Véronique Jean from the Pulmonary Rehabilitation Department in Saint-Jacques Hospital, University Hospital of Nantes and François Dessables from the Tourmaline Medical Center in Nantes.

**Disclosure**

The authors report no conflicts of interest in this work.

![Box plot of changes in *z*-scores of QMVC and 6MWD from baseline to the end of the PRP.\
**Abbreviations:** QMVC, quadriceps maximal voluntary contraction; 6MWD, 6-minute walk distance; PRP, pulmonary rehabilitation program.](copd-13-2685Fig1){#f1-copd-13-2685}

![Distribution of subjects.\
**Notes:** (**A**)Subjects with changes in QMVC and 6MWD in terms of respective MIDs of 7.5 Nm and 30 m; (**B**) subjects with changes in QMVC and SGRQ in terms of respective MIDs of 7.5 Nm and −4 points.\
**Abbreviations:** QMVC, quadriceps maximal voluntary contraction; 6MWD, 6-minute walk distance; MIDs, minimally important differences; SGRQ, St George's respiratory questionnaire.](copd-13-2685Fig2){#f2-copd-13-2685}

###### 

Baseline characteristics of the patients

  ---------------------- ---------
  n                      157
  Male/female            93/64
  Age, years             63±9
  BMI, kg/m^2^           26±6
  Dyspnea, mM RC         2±1
  Lung function          
   FEV~1~, % predicted   47±19
   FVC, % predicted      79±23
   FEV~1~/FVC, %         45±16
   GOLD 1, n (%)         8 (5)
   GOLD 2, n (%)         58 (37)
   GOLD 3, n (%)         64 (41)
   GOLD 4, n (%)         27 (17)
   QMVC, Nm              96±37
   6MWD, m               392±107
   6MWD, % predicted     68±19
   SGRQ total score      53±16
  HADS                   
   Anxiety               8±4
   Depression            7±4
   Total                 15±7
  BODE index             4±2
  ---------------------- ---------

**Notes:** Data presented as mean ± SD unless otherwise indicated. Predicted values for 6MWD taken from Troosters et al.[@b35-copd-13-2685]

**Abbreviations:** BMI, body-mass index; mMRC, modified Medical Research Council (scale); FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; QMVC, quadriceps maximal voluntary contraction; 6MWD, 6-minute walk distance; SGRQ, St George's respiratory questionnaire; HADS, Hospital Anxiety and Depression Scale; BODE, body mass, airflow obstruction, dyspnea, and exercise.

###### 

Changes in parameters measured at baseline and end of PRP

                Baseline   End       Change (absolute)   Change (%)
  ------------- ---------- --------- ------------------- ----------------------------------------------------
  QMVC, Nm      96±37      105±40    9±16                11±19[a](#tfn3-copd-13-2685){ref-type="table-fn"}
  6MWD, m       392±107    438±102   42±50               13±17[a](#tfn3-copd-13-2685){ref-type="table-fn"}
  SGRQ total    53±16      44±16     −9±17               −13±25[a](#tfn3-copd-13-2685){ref-type="table-fn"}
  HADS                                                   
   Anxiety      8±4        7±4       −2±3                −15±47[a](#tfn3-copd-13-2685){ref-type="table-fn"}
   Depression   7±4        5±4       −1±3                −14±52[a](#tfn3-copd-13-2685){ref-type="table-fn"}
   Total        15±7       12±7      −3±6                −18±38[a](#tfn3-copd-13-2685){ref-type="table-fn"}

**Notes:**

*P*\<0.001. Data presented as mean ± SD.

**Abbreviations:** PRP, pulmonary rehabilitation program; QMVC, quadriceps maximal voluntary contraction; 6MWD, 6-minute walk distance; SGRQ, St George's respiratory questionnaire; HADS, Hospital Anxiety and Depression Scale.
